

Hull and East Riding Prescribing Committee Minutes – Confirmed

Date / Time	Wednesday 18 th July 2019, 1:00pm
Venue	The Board Room, Health House, Willerby
Chair	Dr S Raise, GP Prescribing Lead, ER
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No (Approval to be sought from secondary care clinician post meeting)

Mr A Ramirez, Professional Secretary, Senior Principal Pharmacist- Interface HUTH
Dr B Ali, GP Prescribing Lead, Hull
Mrs E Baggaley, Senior Pharmacist, CHCP CIC
Mr K McCorry, Senior Pharmacist, NECS
Miss J Morgan, Senior Principal Pharmacist, HUTH
Mr P Davis, Strategic Lead Primary Care, Hull, CCG
Mrs J Clarke Chief Officer Local Pharmaceutical Committee ERHLPC
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HUTH
Dr W Chong, Chief Pharmacist, HTFT

Apologies	Dr R Schreiber, Medical Secretary, LMC Prof A Morice, Professor of Respiratory Medicine, HUTH Mr G Hill, Senior Pharmacist, CHCP CIC
------------------	--

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2019.07.01	Apologies	As above				7/19
2019.07.02	Declarations of Interest	None				7/19
2019.07.03	Minutes of the Previous Meeting	The minutes of the previous meeting were accepted as a true record. AR informed the committee he had received approval from Prof Morice for documents approved last time				7/19
2019.07.04	Matters Arising & Action Tracker	<p>MHRA Alert – Fluoroquinolones SR still to disseminate fluoroquinolone alert to colleagues.</p> <p>MHRA Alert – Fluoroquinolones KMc informed the committee that the fluorquinolone alert is appearing on the optimise system for Hull and ER.</p> <p>PG/SCF Management of Childhood pathway – comments have been discussed with consultants and Pathway is on agenda for discussion.</p> <p>RMOC AR has discussed heparinised saline with HUTH depts. QCOH are still working on documentation and reviewing the processes</p> <p>Correspondence Received AR/KMc attended flash glucose monitoring meeting with endocrinology. On the agenda for discussion.</p> <p>Traffic Light Status WH has updated the red list and joint formulary.</p> <p>Feedback from Commissioning Groups KMc has shared commissioning decision regarding Methotrexate and Esmya with AR</p> <p>PG/SCF AR has amended documents and added to website.</p> <p>PG/SCF SCF Ullipristal Acetate (Esmya) for treatment of Uterine Fibroids with heavy menstrual periods. KMc informed the committee that the CCG</p>	<p>SR to do</p> <p>Action complete</p> <p>On agenda for discussion</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>SR</p> <p>KMc</p> <p>AR</p> <p>AR</p> <p>AR/KMc</p> <p>WH</p> <p>KMc</p> <p>AR</p> <p>KMc</p>	<p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>have approved this SCF</p> <p>PG/SCF SCF Methotrexate for immunosuppression in adults - KMc informed the committee that the CCG have approved this SCF with comments and changes. AR has modified the document accordingly and will be on website soon. HUTH will give patients initial 1l waste bin and GPs will prescribe 5l bins thereafter</p> <p>PG/SCF WH has removed withdrawn SCF from the website</p> <p>Out of Hours Service AR has added document to website</p> <p>Red Drugs On SCR AR has shared SCR guideline for third party drugs with practice pharmacists</p> <p>AOB JC has shared sucralfate information with LPC</p> <p>AOB AR has updated antibiotic guideline to include nitrofurantoin</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>KMc</p> <p>WH</p> <p>AR</p> <p>AR</p> <p>JC</p> <p>AR</p>	<p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p> <p>7/19</p>
2019.07.05	Traffic Light Status	<p>Benzbromarone – to be added to joint formulary as RED – this is an unlicensed preparation for the treatment of gout</p> <p>Pristinamycin – to be added to joint formulary as RED- this is an unlicensed preparation for the treatment of gram positive bacterial infection</p> <p>Sodium Chloride 5% Eye Drops – formulary status to be changed from RED to Blue.</p>	<p>Approved as RED</p> <p>Approved as RED</p> <p>Approved as blue</p>	WH to update the joint formulary	WH	9/19
2019.07.06	Feedback From Commissioning Groups	None				
2019.07.07	Prescribing guidelines, shared	NEW Asthma Pathway – Modified drugs pathway in line with joint formulary	Approved	For website	AR	9/19

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
	care frameworks for approval	<p>Pirfenidone for idiopathic pulmonary fibrosis. Guidance for local hospitals and GPs</p> <p>Nintedanib for idiopathic pulmonary fibrosis. Guidance for local hospitals and GPs</p> <p>Both documents have been written by the respiratory dept to provide information for GPs. The three main points of the documents are:</p> <ol style="list-style-type: none"> 1) Add red item to SCR 2) Arrange phlebotomy 3) Make sure safe systems are in place to monitor drug and to communicate blood results <p>There was a discussion around the responsibility of GPs when performing phlebotomy and interpreting blood results. It was agreed that LMC input into this document was required, as more clarity is required regarding responsibilities</p> <p>PD suggested that the CCG enhanced service could encompass some of this work, it was also suggested that adding the line “This drug needs to be added to the patients SCR”, to clinic letters could help GPs to comply with this requirement.</p> <p>UPDATES</p> <p>Constipation Guideline Lubiprostone needs removing from page 2 as is discontinued. To add lifestyle advice on top of page 2.</p> <p>Localised protocol for outbreaks of influenza in Care Homes Hull and the East Riding of Yorkshire (for in season and out of season) Add “influenza like illness” in first instance not just ILI, alter HEY to HUTH</p> <p>Testosterone Shared Care Framework Updated to include Testavan as first line option</p>	<p>AR/SR to write to the authors with the committees concerns</p> <p>AR to discuss with LMC</p> <p>Approved with amendments</p> <p>Approved with amendments</p> <p>Approved with amendment</p>	<p>AR/SR to write</p> <p>AR to speak to LMC</p> <p>AR to amend and add to website</p> <p>AR to amend and add to website</p> <p>AR to amend and add to website</p>	<p>AR/SR</p> <p>AR</p> <p>AR</p> <p>AR</p> <p>AR</p>	<p>9/19</p> <p>9/19</p> <p>9/19</p> <p>9/19</p> <p>9/19</p>
2019.07.08	Regional Medicines Optimisation Committee	<p>Newsletter Number 5</p> <p>AR informed the committee that HUTH had switched 87% of Adalimumab patients and was now looking at switching paediatric patients</p> <p>Rarely-Used-Medicines-How-to-view-them-on-Define</p> <p>RMOC-Position-Statement-Rarely-Used-and-Urgent-Medicines</p> <p>Outline Specification for CSU collaborative to support shared care</p>	<p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p>	<p>No further action</p>		<p>9/19</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>programme This collaboration is looking at national shared care frameworks in view to have a nation Amber list and standards SCF</p>				
2019.07.09	Correspondence Received	<p>Items-which-should-not-be-routinely-prescribed-in-pc-ccg-guidance AR is arranging to meet cardiology team to discuss SCF for Amiodarone. There were concerns regarding the recommendation to not prescribe safety needles and the impact this has on community services, it was agreed that this issue was to be picked up outside of the meeting.</p> <p>Draft Commissioning Statement for Flash Glucose Monitoring Systems Both CCGs have approved but clarity regarding waste bins is still required. JC has informed the committee that Abbott are struggling to meet demand and are not accepting new patients at present. Supply to existing pharmacies has also been restricted. JC has emailed the chairman of RMOC north regarding waste disposal of this product</p> <p>DOAC Proposal There was a long discussion around this proposal. The committee felt that the document needed clarification as the purpose and drivers of the proposal. AR to write to authors to request an amended document to address the committee's concerns. To note that HERPC has assumed that the proposal is to make Edoxaban the first line agent for new patients for primary prevention in AF, based on cost effectiveness (rebate scheme) and that it's not supporting actively switching established patients.</p>	<p>AR to discuss amiodarone SCF with cardiology.</p> <p>GPs to prescribe 7l bins and endocrinology to explain process to patients</p> <p>AR to write to authors</p>	<p>AR to speak to endocrinology</p>	<p>AR</p> <p>AR</p> <p>AR</p>	<p>9/19</p> <p>9/19</p> <p>9/19</p>
2019.07.10	Primary Care Rebate Scheme	Nothing this month				7/19
2019.07.11	Additional Minutes for Information	<p>a)MMIG (May, June) b) HEY D&T (May) c) HTFT DTC (April) d) CHCP e) Formulary Sub Group (June 19 Draft) f) Hull Planning & Commissioning Committee (March & April)</p>	Noted			7/19
2019.07.12	A.O.B	AR informed the committee that there had been 3 instances of patients being admitted to hospitals where the GP had not update the SCR. AR would like to know who to raise these issues in within the CCG.	It was agreed that AR should speak to April Daniel at HUTH as this was a governance	AR to speak to HUTH governance	AR	9/19

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		AR informed the committee that the Julie Curran had updated the catheter formulary to remove Optilube (device) and change to Instillagel (medicine)	issue. PD agreed to arrange for Hull CCG to contact AR AR to update	PD to ask CCG to contact AR	PD AR	9/19 9/19
	Date and Time of Next Meeting	Wednesday 25th September 2019 1pm – 3pm, Board Room, Health House, Willerby, Hull				